Clinical Trials Browser

balstilimab × Sarcoma × Clear all

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT06751524 2024-12-30

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Available

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Phase 2 Withdrawn

Sarcoma

Hemangiosarcoma

Clinical Trials

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma